Proactive Investors - Run By Investors For Investors

G1 Therapeutics jumps after announcing breast-cancer drug trilaciclib extended lives of patients on chemotherapy

Phase 2 trial demonstrated that women with metastatic triple-negative breast cancer lived significantly longer when receiving trilaciclib and chemotherapy compared with women receiving chemotherapy alone
breast cancer
The company expects to submit marketing applications in the US and Europe in 2020 to use trilaciclib to treat small-cell lung cancer

Shares of G1 Therapeutics Inc (NASDAQ:GTHX) increased by double-digits Tuesday after announcing its breast-cancer drug trilaciclib, when combined with chemotherapy, extended patients’ lives.

The company said results from a randomized Phase 2 trial of 102 patients demonstrated that women with metastatic triple-negative breast cancer (TNBC) lived significantly longer when receiving trilaciclib and chemotherapy compared with women receiving chemotherapy alone.

G1’s stock jumped 35% to $26.59 a share on strong volume. 

READ: G1 Therapeutics shares jump on new drug application

“Triple-negative breast cancer is the most aggressive type of breast cancer, and women diagnosed with metastatic TNBC need new treatment options," said CEO Mark Velleca. "We look forward to sharing these data with regulators, as well as presenting findings from this trial at a medical meeting later this year.” 

G1 is a clinical-stage biopharmaceutical company based in Research Triangle Park, North Carolina.

The company expects to submit marketing applications in the US and Europe in 2020 to use trilaciclib to treat small-cell lung cancer.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

View full GTHX profile View Profile

Related Articles

patch
May 20 2019
The New Jersey company's lead product is Twirla, a low-dose prescription contraceptive applied once weekly for three weeks, followed by a week without the patch
scientist at petrie dish
May 15 2019
Here we take a closer look at Midatech Pharma PLC (LON:MTPH)
Scientist at work
May 28 2019
CaPre, a potent form of Omega-3, has been shown to reduce triglycerides, but also lower 'bad cholesterol' levels, and raise 'good' ones

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use